AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00970957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin Intravitreal Injection
Description: Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol
Study NCT00970957 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Avastin Intravitreal Injection
Description: Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
Study NCT04585295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine
Description: 50 mg/kg Betaine consumed twice daily for 7 days.
Study NCT04585295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA Big 6
Description: 1 level scoop (\~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.
Study NCT04585295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50 mg/kg Placebo consumed twice daily for 7 days.
Study NCT06373172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual simulation-based education program
Description: We used vSim® for Nursing - Nursing Medical-Surgical as the virtual simulation-based education program. Four modules were included: (a) acute myocardial infarction, (b) diabetes mellitus, (c) transfusion, and (4) asthma. Each module learning sessions was conducted based on scenarios, which consisted of five steps: Suggested reading, Pre-simulation quiz, vSim, Post-simulation quiz, and Guide reflection questions. For each module, the intervention was performed for two hours. The participants attended four module learning sessions and received eight hours of training. Debriefing using guided reflection questions were completed in the form of a team reflection, followed by an instructor-learner discussion and feedback for 20 minutes of each module.
Study NCT00165841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole 20 mg
Description: rabeprazole sodium tablet 20 mg once daily
Study NCT00165841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Description: rabeprazole sodium tablet 20 mg once daily
Study NCT01502982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOEP14x6+HD-AraC+HD-Mtx
Description: rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
Study NCT03348852 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.
Study NCT03348852 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.
Study NCT00301028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Beginning weekly dose 400 mg/m\^2 IV over 1-2 hours, and 250 mg/m\^2 weeks 2-6.
Study NCT03903159 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive Peer Journaling (PPJ)
Description: PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve quality of life in recovery and reduce relapse. PPJ uses standard lined journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health.
Study NCT00301028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 weekly for 6 courses.
Study NCT00301028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135 mg/m\^2 weekly for 6 courses.
Study NCT04001842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction of the mandible using an axially vascularized bone construct
Description: Surgically reconstructing defects of the mandible using reconstruction plate and Titanium mesh filled with an artificial bone substitute to form a bone construct. This construct will be vascularized at the same operation using a vein graft from the forearm. The vein graft will be microsurgically connected to an artery and vein within the facial/neck region to provide a vascular supply to the construct (arterio venous loop)
Study NCT05041985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Tablets
Description: Diazepam 5 mg tablet once per day (bedtime) for 7 days
Study NCT01295489 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01323192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNS001
Description: Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
Study NCT01323192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo orally once daily for 8 weeks.
Study NCT01246960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered intravenously
Study NCT00301028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Following induction in second part of study.
Study NCT00301028 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Following induction in second part of study.
Study NCT00231244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER Sirolimus-Eluting Coronary Stent
Description: CYPHER Sirolimus-Eluting Coronary Stent
Study NCT00423735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT00423735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03822572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endurance exercise
Description: defined exercise program
Study NCT03822572 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: habitual physical activity before the diagnosis
Study NCT01841437 — intervention group
Intervention type: DEVICE
Intervention: iStent
Study NCT00835952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: ATX-101 single doses
Study NCT01384240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine Hemisulfate
Description: 3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
Study NCT02671942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Study NCT02671942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01919905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
Study NCT01919905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
Study NCT01887392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge Translation Education Sessions
Description: Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
Study NCT03751891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audéo B90-Direct
Description: The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
Study NCT03751891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HearingAid_A
Description: HearingAid_A is the most recent Receiver-in-the-canal Hearing aid from manufacturer_A which will be fitted to the participants individual Hearing loss.
Study NCT03751891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HearingAid_B
Description: HearingAid_B is the most recent Receiver-in-the-canal Hearing aid from manufacturer_B which will be fitted to the participants individual Hearing loss.
Study NCT01517815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem or Piperacillin/Tazobactam
Description: This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value.
Study NCT01517815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem or Piperacillin/Tazobactam
Description: This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value.
Study NCT02468388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maltitol
Description: maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day
Study NCT02468388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: xylitol
Description: xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day
Study NCT02468388 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gum base
Description: gum base: 99% gum base; two pellets for 10 min five times each day
Study NCT02987803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data
Description: The tool displays star ratings of hospitals on how labor-friendly they are. The star ratings (1 through 5) are based on hospital-level cesarean delivery rates. The data comes from The Leapfrog Group and is supplemented by publicly available state data. The data displayed will be customized to the users geographic location.
Study NCT03686020 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme Linked Immunosorbent assay (ELISA)
Description: measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)
Study NCT03323723 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SUI Device
Description: Pessary SUI device
Study NCT01369602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: single dose 300-mg
Study NCT04438590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kelulut Honey
Description: The Substance being tested to be used as an alternative
Study NCT04438590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carborie
Description: The commercially available substance
Study NCT00655850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: * Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:~* Dexamethasone 20mg, intravenously (IV)~* Diphenhydramine 50 mg IV~* Ranitidine 50 mg IV~* Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.~* The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)~Paclitaxel Dose Levels:~* Dose Level 1 ________80 mg/m2/weekly~* Dose Level -1 ________70 mg/m2/weekly
Study NCT00655850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Premedication~* Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.~* Prior to receiving paclitaxel chemotherapy~* Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.~* The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.~Gemcitabine Dose Levels:~* Dose Level 2 ________300 mg/m2/weekly~* Dose Level 1 ________200 mg/m2/weekly~* Dose Level -1 ________150 mg/m2/weekly
Study NCT00655850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avastin
Description: * The dose of Avastin is 10 mg/kg IV every 2 weeks~* It will be administered following the administration of chemotherapy~* The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.~* It should not be administered or mixed with dextrose solutions.
Study NCT02813421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM Informed
Study NCT02760264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 0.25 mg/kg/day
Description: Oral administration of 0.25 mg/kg/day daily for 14 days.
Study NCT02760264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 0.75 mg/kg/day
Description: Oral administration of 0.75 mg/kg/day daily for 14 days.
Study NCT02760264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 2.0 mg/kg/day
Description: Oral administration of 2.0 mg/kg/day daily for 14 days.
Study NCT02760264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 6.0 mg/kg/day
Description: Oral administration of 6 mg/kg/day daily for 14 days.
Study NCT00911807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin + donepezil
Description: Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.
Study NCT00911807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin + placebo
Description: Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Placebo for donepezil was given PO once daily during the whole study duration (28 weeks).
Study NCT00911807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil + placebo
Description: Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.
Study NCT01088282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Implantation of multifocal or monofocal IOL
Study NCT01088282 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Cataract surgery
Description: Implantation of multifocal or monofocal IOL
Study NCT03490474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Inducing Massage
Description: Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
Study NCT03490474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Free Massage
Description: Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
Study NCT03490474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coldpressor
Description: Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
Study NCT03589248 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GIF score
Description: assessment by GIF score
Study NCT03589248 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: US score
Description: assessment by ultrasonography score
Study NCT01829113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427
Description: Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
Study NCT01829113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
Study NCT01246960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously
Study NCT01246960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Administered intravenously
Study NCT01246960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously
Study NCT01246960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: Administered intravenously
Study NCT01246960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously
Study NCT01246960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: Administered intravenously
Study NCT05239559 — intervention group
Intervention type: DEVICE
Intervention: Bubble CPAP oxygen delivery device
Description: In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the nasopharynx of the baby. An underwater tube (expiratory arm) that acts as a blow off valve is interposed between the oxygen source and the baby. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the baby. The constant bubbling of gas through the blow off mechanism delivers the bubbling CPAP effect. Oxygen may be delivered by nasal prongs inserted into the nostril of child.~The system has three components:~1. Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~2. A nasal interface connecting the child's airway with the circuit:~3. An expiratory arm with the distal end submerged in water to generate end-expiratory pressure.~The source of oxygen will be either an oxygen concentrator or cylinder, central distribution through pipelines.
Study NCT03156595 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nurse interview
Description: Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
Study NCT00313950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella
Description: 0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
Study NCT03156595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis sessions
Description: Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.